Natural killer cell receptors
Research type
Research Study
Full title
Natural killer cell receptors
IRAS ID
206084
Contact name
David Adams
Contact email
Sponsor organisation
Genome Research Ltd
Duration of Study in the UK
2 years, 1 months, 20 days
Research summary
We are a team of researchers at the Wellcome Sanger Institute and have been funded from Open Targets (a consortium of Biogen, Celgene, EMBL-EBI, GlaxoSmithKline, Takeda, and the Wellcome Sanger Institute, http://opentargets.org/about). We are trying to find new interactions between cancer cells and the immune system, focussing on Natural Killer (NK) cells. We aim to identify new interactions using in vitro assays and then understand the functional importance using NK cells isolated from peripheral blood and determining how well they kill a range of cancer cells which express differing levels of these newly identified interactors. This functional information will be used to investigate the role of these proteins in cancer biology and develop new therapies
REC name
Yorkshire & The Humber - Leeds West Research Ethics Committee
REC reference
18/YH/0301
Date of REC Opinion
30 Jul 2018
REC opinion
Favourable Opinion